Recently, Junhemeng Biopharmaceutical (Hangzhou) Co., Ltd. (君合盟生物制药（杭州）有限公司) (hereinafter referred to as “Junhemeng”) has successively completed Series A and Series A+ financing of hundreds of millions of yuan. Series A financing was led by Tonghua County State-Owned Assets Investment Holding Group Co., Ltd. (通化国投) and followed by many institutions such as Guangdian Capital (光点资本); Series A+ financing was jointly invested by the original shareholders, Guangdian Capital and 3E Bioventures Capital (本草资本). The funds will be used to further promote the clinical trials of Junhemeng’s growth hormone products and to continuously enrich Junhemeng’s technology accumulation and product innovation. JT&N, as legal counsel to Junhemeng, has assisted Junhemeng in successively completing Series Pre-A financing, Series A financing and Series A+ financing totaling hundreds of millions of yuan.
Established in November 2020, Junhemeng is a pharmaceutical company focused on the development of cutting-edge protein drugs. It is mainly engaged in the early discovery, drug development and commercialization of innovative biotech drugs in the endocrine and metabolic fields. At present, Junhemeng’s R&D is focused on the frontier protein drug field with broad market prospects, among which the leading products are recombinant protein drugs such as recombinant botulinum toxin type A and growth hormone. With more than 20 years of experience in protein drug research and industrialization, Junhemeng’s R&D team has successfully developed a series of products such as insulin analogs, GLP-1 receptor agonists, commercial reference enzymes, etc.
In this project, JT&N’s senior partner Chaoping DI, partner Jialun WEN, attorneys Junyi CAI and Lingling YU and other attorneys jointly provided a full range of legal services, including, but not limited to, negotiating with investors on behalf of Junhemeng, assisting Junhemeng in receiving due diligence from investors, drafting transaction documents such as the investment agreement, and assisting Junhemeng in completing the investment delivery.
阅读原文